+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genitourinary Drugs Market - Global Forecast 2026-2032- Product Image
Genitourinary Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Genitourinary Drugs Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5454847
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Genitourinary Drugs Market is projected to reach USD 43.33 Billion in 2026. It is expected to continue growing at a CAGR of 4.32%, reaching USD 55.88 Billion by 2032.

The genitourinary drugs market spans therapies for urinary tract infections, benign prostatic hyperplasia, overactive bladder, erectile dysfunction, endometriosis-related urogenital symptoms, and urologic cancers, including prostate, bladder, and kidney cancer.

Market momentum is also being shaped by population aging, improved screening, broader use of specialty medicines, antimicrobial resistance, and payer scrutiny over value. Industry leaders are competing on clinical differentiation, durable safety data, patient adherence, and evidence that supports faster formulary access across hospital, retail, specialty, and public procurement channels.

Transformative Shifts Reshaping Genitourinary Care

The landscape is shifting from symptom control toward precision, prevention, and disease-modifying care. In urologic oncology, androgen receptor pathway inhibitors, immune checkpoint inhibitors, antibody-drug conjugates, targeted therapies, and radioligand approaches are changing treatment sequencing for prostate, bladder, and kidney cancers. In non-oncology segments, beta-3 agonists, improved alpha-blocker strategies, phosphodiesterase type 5 inhibitors, and combination regimens are advancing convenience and adherence.

A second structural shift is the rising importance of stewardship and evidence-based prescribing. Antimicrobial resistance has made uncomplicated and recurrent urinary tract infection management more complex, pushing drug developers and health systems toward rapid diagnostics, narrower-spectrum agents, non-antibiotic prevention, and real-world surveillance. At the same time, regulatory agencies and payers increasingly expect comparative data, patient-reported outcomes, and durable safety evidence.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact across discovery, clinical development, commercialization, and pharmacovigilance. AI-enabled target identification, molecular screening, biomarker discovery, and imaging analytics are particularly relevant in prostate, bladder, and kidney cancer, where patient stratification can improve trial efficiency and treatment selection. Regulators, including the U.S. FDA, have reported growing use of AI and machine learning in drug development submissions, reflecting broader adoption across the life sciences sector.

In genitourinary drugs, AI can also improve trial site selection, predict recruitment bottlenecks, analyze real-world evidence from electronic health records, and identify safety signals earlier. The strongest near-term value will come from governed AI models that combine clinical validity, transparent data provenance, bias monitoring, and compliance with privacy regulations such as HIPAA and GDPR.

Key Regional Insights Across Global Markets

Asia-Pacific is becoming a high-priority arena as China and India expand access to generics, biosimilars, oncology medicines, and hospital-based specialty care, while Japan, South Korea, and Australia drive demand for aging-related urology and cancer treatments. The region’s large patient base, increasing diagnostic capacity, and expanding domestic pharmaceutical manufacturing are strengthening both treatment access and competitive intensity.

North America remains a leading innovation and revenue center because of FDA pathways, high oncology adoption, strong specialty pharmacy infrastructure, and substantial R&D investment. Europe benefits from EMA oversight, mature reimbursement systems, and aging populations, while the EU Health Technology Assessment Regulation is increasing the importance of comparative clinical evidence. Latin America, led by Brazil and Mexico, is expanding access through public formularies and generics, although affordability and reimbursement variability remain constraints. The Middle East, especially GCC markets, is investing in specialty care and centralized procurement, while Africa’s opportunity is anchored in access expansion, infection management, diagnostics, and reliable supply of essential genitourinary medicines.

Key Group Insights for Strategic Positioning

ASEAN markets are gaining relevance as Indonesia, Vietnam, Thailand, Malaysia, and the Philippines expand healthcare coverage, retail pharmacy reach, and local manufacturing partnerships. Access strategies must account for country-specific reimbursement, physician education, and pricing sensitivity. GCC countries, supported by high per-capita health spending and government-led procurement, are prioritizing specialty care, oncology access, and formulary discipline, making tender readiness and value evidence essential.

The European Union is advancing harmonized assessment and stronger evidence requirements, increasing the need for robust comparative outcomes and real-world data. BRICS countries combine large patient populations with growing domestic production, creating opportunities for localized manufacturing, generics, and differentiated specialty launches. G7 markets remain the strongest centers for premium innovation, clinical research, and early adoption, while NATO-aligned supply chain resilience initiatives are elevating attention to pharmaceutical security, active ingredient sourcing, and continuity planning.

Key Country Insights for Market Prioritization

The United States leads in specialty genitourinary oncology uptake, clinical trial activity, and FDA-approved innovation, while Canada emphasizes evidence-based reimbursement and pan-Canadian pricing discipline. Mexico and Brazil are important Latin American access markets where public procurement, private insurance, and generics shape adoption. In Europe, the United Kingdom, Germany, France, Italy, and Spain combine aging demographics with strong urology networks, but national health technology assessment processes create distinct evidence and pricing expectations.

Russia remains influenced by localization policies and public procurement dynamics. China is scaling oncology access through regulatory reform, volume-based procurement, and domestic innovation, while India’s strength lies in generics, cost-efficient manufacturing, and high-volume treatment needs. Japan faces significant aging-related demand and values safety, quality, and reimbursement discipline; South Korea is strong in digital health and clinical research; and Australia offers a transparent reimbursement environment supported by established cancer care pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical evidence, including head-to-head data, patient-reported outcomes, durable safety findings, and real-world effectiveness. In urologic oncology, companies need biomarker strategies, sequencing evidence, and payer-ready value dossiers. In infection-focused portfolios, antimicrobial stewardship, rapid diagnostic alignment, and resistance surveillance should be embedded into launch planning.

Commercial strategies should be localized by reimbursement model, procurement pathway, and care setting. Manufacturers can improve resilience by diversifying active pharmaceutical ingredient sourcing, strengthening pharmacovigilance, investing in adherence support, and partnering with health systems on data generation. AI adoption should focus on validated use cases with measurable impact on R&D productivity, trial execution, medical affairs, and post-market safety.

Research Methodology and Data Validation

This executive summary is based on a structured secondary research approach using publicly available and authoritative sources, including WHO, CDC, FDA, EMA, ECDC, NIH, National Cancer Institute, GLOBOCAN 2022, OECD, World Bank, United Nations demographic datasets, peer-reviewed journals, clinical trial registries, regulatory labels, and health technology assessment documents.

Insights were triangulated across epidemiology, regulatory developments, reimbursement trends, clinical innovation, patent activity, and regional healthcare infrastructure. Data points were used only where supported by credible sources, and qualitative conclusions were validated through consistency checks across multiple references to ensure relevance for strategic planning in the genitourinary drugs market.

Conclusion and Strategic Outlook

The genitourinary drugs market is advancing through a combination of demographic demand, oncology innovation, infection-control needs, and expanding access in emerging economies. Urologic cancers, recurrent urinary tract infections, benign prostatic hyperplasia, and overactive bladder will continue to support broad therapeutic demand, while payer expectations and antimicrobial resistance will raise the bar for evidence.

Organizations that combine clinical differentiation, responsible stewardship, regional access expertise, AI-enabled execution, and resilient supply chains will be best positioned. The market’s next phase will reward stakeholders that can deliver measurable patient outcomes while navigating increasingly complex regulatory, pricing, and procurement environments.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Genitourinary Drugs Market, by Drug Class
7.1. Introduction
7.2. Antimicrobials
7.2.1. Antibiotics
7.2.2. Antifungals
7.2.3. Antivirals
7.2.4. Antiparasitics
7.3. Alpha Adrenergic Blockers
7.4. 5 Alpha Reductase Inhibitors
7.4.1. Type 1 Inhibitors
7.4.2. Type 2 Inhibitors
7.5. Phosphodiesterase Type 5 Inhibitors
7.6. Urinary Analgesics
7.7. Hormonal Therapies
7.7.1. Androgens
7.7.2. Estrogens
7.7.3. Progestins
7.8. Alkylating & Cytotoxic Agents
8. Genitourinary Drugs Market, by Indication
8.1. Introduction
8.2. Urinary Tract Infections
8.2.1. Uncomplicated UTI
8.2.2. Complicated UTI
8.2.3. Recurrent UTI
8.3. Benign Prostatic Hyperplasia
8.4. Erectile Dysfunction
8.5. Female Sexual Dysfunction
8.6. Urinary Incontinence
8.7. Overactive Bladder
8.8. Sexually Transmitted Infections
8.8.1. Chlamydia
8.8.2. Gonorrhea
8.8.3. Syphilis
8.8.4. Trichomoniasis
8.9. Bladder Disorders
9. Genitourinary Drugs Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Intramuscular
9.2.3. Subcutaneous
9.3. Oral
9.3.1. Tablets
9.3.2. Capsules
9.3.3. Oral Suspensions
9.4. Topical
9.4.1. Creams
9.4.2. Gels
10. Genitourinary Drugs Market, by End User
10.1. Introduction
10.2. Specialty Clinics
10.2.1. Urology Clinics
10.2.2. Gynecology Clinics
10.2.3. Nephrology Clinics
10.3. Homecare Settings
10.4. Hospitals
10.5. Research & Academic Institutes
10.6. Ambulatory Surgical Centers
11. Genitourinary Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Offline
11.3. Online
12. Genitourinary Drugs Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Genitourinary Drugs Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Genitourinary Drugs Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AbbVie Inc.
16.2. Amgen Inc.
16.3. Aspen Pharmacare Holdings Limited
16.4. Astellas Pharma Inc.
16.5. AstraZeneca PLC
16.6. Aurobindo Pharma Limited
16.7. Bayer AG
16.8. Boehringer Ingelheim International GmbH
16.9. Boston Scientific Corporation
16.10. Bristol-Myers Squibb Company
16.11. Cipla Limited
16.12. Dr. Reddy's Laboratories Limited
16.13. Eli Lilly and Company
16.14. F. Hoffmann-La Roche Ltd
16.15. Gilead Sciences Inc.
16.16. GSK plc
16.17. Johnson & Johnson
16.18. Kissei Pharmaceutical Co. Ltd.
16.19. Melinta Therapeutics LLC
16.20. Merck & Co. Inc.
16.21. Novartis AG
16.22. Pfizer Inc.
16.23. Sanofi S.A.
16.24. Sun Pharmaceutical Industries Limited
16.25. Takeda Pharmaceutical Company Limited
16.26. Teva Pharmaceutical Industries Ltd.
16.27. UroGen Pharma Ltd
16.28. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL GENITOURINARY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL GENITOURINARY DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL GENITOURINARY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIMICROBIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIMICROBIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIFUNGALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIFUNGALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIFUNGALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ANTIPARASITICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANTIPARASITICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANTIPARASITICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ALPHA ADRENERGIC BLOCKERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ALPHA ADRENERGIC BLOCKERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ALPHA ADRENERGIC BLOCKERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL 5 ALPHA REDUCTASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL 5 ALPHA REDUCTASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL 5 ALPHA REDUCTASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TYPE 1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TYPE 1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TYPE 1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL TYPE 2 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL TYPE 2 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PHOSPHODIESTERASE TYPE 5 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PHOSPHODIESTERASE TYPE 5 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PHOSPHODIESTERASE TYPE 5 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL URINARY ANALGESICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL URINARY ANALGESICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL URINARY ANALGESICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ANDROGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ANDROGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ANDROGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ESTROGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ESTROGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ESTROGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PROGESTINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PROGESTINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PROGESTINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ALKYLATING & CYTOTOXIC AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ALKYLATING & CYTOTOXIC AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ALKYLATING & CYTOTOXIC AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL URINARY TRACT INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL UNCOMPLICATED UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL COMPLICATED UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL COMPLICATED UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL COMPLICATED UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL RECURRENT UTI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RECURRENT UTI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RECURRENT UTI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL BENIGN PROSTATIC HYPERPLASIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FEMALE SEXUAL DYSFUNCTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL FEMALE SEXUAL DYSFUNCTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL FEMALE SEXUAL DYSFUNCTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL URINARY INCONTINENCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL OVERACTIVE BLADDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL OVERACTIVE BLADDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL OVERACTIVE BLADDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SEXUALLY TRANSMITTED INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL CHLAMYDIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CHLAMYDIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CHLAMYDIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GONORRHEA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL GONORRHEA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GONORRHEA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SYPHILIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SYPHILIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SYPHILIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL TRICHOMONIASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL TRICHOMONIASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL TRICHOMONIASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL BLADDER DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL BLADDER DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL BLADDER DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL ORAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL UROLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL UROLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL UROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL GYNECOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL NEPHROLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL NEPHROLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL NEPHROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL RESEARCH & ACADEMIC INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL ONLINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 195. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 196. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 197. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 210. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 211. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 212. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 213. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 214. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 215. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 216. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 217. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 218. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 220. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 221. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 222. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 224. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 225. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 226. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 227. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 228. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 229. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 230. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 231. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 235. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 236. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 237. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 241. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 242. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 243. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 244. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 245. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 246. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 247. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 248. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 250. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 251. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 252. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 254. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 255. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 257. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 258. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 259. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 260. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 261. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 262. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 263. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 264. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 265. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 266. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 267. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 268. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 269. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 270. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 271. GCC GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 272. GCC GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 273. GCC GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 274. GCC GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 275. GCC GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 276. GCC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 277. GCC GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 278. GCC GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 279. GCC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 280. GCC GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 281. GCC GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 282. GCC GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 283. GCC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 284. GCC GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 285. GCC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 289. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 290. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. BRICS GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 302. BRICS GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 303. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 304. BRICS GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 305. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 306. BRICS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 307. BRICS GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 308. BRICS GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 309. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 310. BRICS GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 311. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 312. BRICS GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 313. BRICS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. BRICS GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 315. BRICS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 316. G7 GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 317. G7 GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 318. G7 GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 319. G7 GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 320. G7 GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 321. G7 GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 322. G7 GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 323. G7 GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 324. G7 GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 325. G7 GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 326. G7 GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 327. G7 GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 328. G7 GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 329. G7 GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 330. G7 GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 331. NATO GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 332. NATO GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 333. NATO GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 334. NATO GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 335. NATO GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 336. NATO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 337. NATO GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 338. NATO GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 339. NATO GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. NATO GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 341. NATO GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 342. NATO GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 343. NATO GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. NATO GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 345. NATO GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 346. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 347. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 348. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 349. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ANTIMICROBIALS, 2017-2032 (USD MILLION)
TABLE 350. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 351. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPIES, 2017-2032 (USD MILLION)
TABLE 352. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 353. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, 2017-2032 (USD MILLION)
TABLE 354. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, 2017-2032 (USD MILLION)
TABLE 355. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 356. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 357. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 358. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 359. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 360. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, 2017-2032 (USD MILLION)
TABLE 361. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 362. CANADA GENITOURINARY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 363. CANADA GENITOURINARY DRUGS MARKET SIZE,

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc.
  • GSK plc
  • Johnson & Johnson
  • Kissei Pharmaceutical Co. Ltd.
  • Melinta Therapeutics LLC
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UroGen Pharma Ltd
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 43.33 Billion
Forecasted Market Value ( USD ) by 2032 $ 55.88 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Genitourinary Drugs Market Report by Indication, Product, and Region 2026-2034 - Product Image

Genitourinary Drugs Market Report by Indication, Product, and Region 2026-2034

  • Report
  • 137 Pages
  • Global
From
Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 180 Pages
  • Global
From
Genitourinary Drugs Market Report 2026 - Product Image

Genitourinary Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Genitourinary Drugs - Global Strategic Business Report - Product Image

Genitourinary Drugs - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2026-2032 - Product Image

Benign Prostatic Hypertrophy Drugs Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From

About the Market

The Genitourinary Drug market is a subset of the pharmaceutical industry that focuses on drugs used to treat urological disorders. These drugs are used to treat a variety of conditions, including urinary tract infections, bladder control issues, kidney stones, and prostate enlargement. Genitourinary drugs are also used to treat erectile dysfunction, infertility, and other sexual health issues. These drugs are typically prescribed by urologists and other healthcare professionals. The Genitourinary Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, AstraZeneca, Sanofi, and Bayer. Other companies in the market include Allergan, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.